Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.
Zambelli V et al.
Endocrine Pathology, 2025
Molecular profiling of oral epithelial dysplasia and oral squamous cell carcinoma using next generation sequencing.
Krishnan RP et al.
Journal of Stomatology, Oral and Maxillofacial Surgery, 2025
Somatic mutation detection and KRAS amplification in testicular germ cell tumors.
Cabral ERM et al.
Frontiers in Oncology, 2023
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status.
Reder H et al.
Cancer Medicine, 2021
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Nassar AH et al.
British Journal of Cancer, 2020
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.
Ip CKM et al.
Nature Communications, 2018
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T et al.
Bmc Cancer, 2018
Toward the molecular dissection of peritoneal pseudomyxoma.
Pietrantonio F et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2016
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Clynick B et al.
The Journal of Molecular Diagnostics : Jmd, 2015
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
Siroy AE et al.
The Journal of Investigative Dermatology, 2015